Amplia Therapeutics Limited (ATX.AX)
AUD 0.05
(-1.92%)
AUD 0.05
(-1.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -4.42 Million AUD | 40.81% |
| 2023 | -7.47 Million AUD | -32.85% |
| 2022 | -5.62 Million AUD | -45.21% |
| 2021 | -3.87 Million AUD | -71.53% |
| 2020 | -2.25 Million AUD | -17.28% |
| 2019 | -1.92 Million AUD | 60.08% |
| 2018 | -4.82 Million AUD | 46.19% |
| 2017 | -8.96 Million AUD | -22.67% |
| 2016 | -7.31 Million AUD | -35.44% |
| 2015 | -5.39 Million AUD | -32.02% |
| 2014 | -4.08 Million AUD | -34.93% |
| 2013 | -3.03 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -9.02 Million AUD | -20.7% |
| 2024 Q2 | -3.6 Million AUD | 0.0% |
| 2024 Q4 | -3.34 Million AUD | 0.0% |
| 2023 Q4 | -2.79 Million AUD | 0.0% |
| 2023 FY | -7.47 Million AUD | -32.85% |
| 2023 Q2 | -4.67 Million AUD | 0.0% |
| 2022 Q4 | -3.54 Million AUD | 0.0% |
| 2022 Q2 | -2.08 Million AUD | 0.0% |
| 2022 FY | -5.62 Million AUD | -45.21% |
| 2021 Q4 | -2.44 Million AUD | 0.0% |
| 2021 FY | -3.87 Million AUD | -71.53% |
| 2021 Q2 | -1.42 Million AUD | 0.0% |
| 2020 Q4 | -1.37 Million AUD | 0.0% |
| 2020 Q2 | -888.94 Thousand AUD | 0.0% |
| 2020 FY | -2.25 Million AUD | -17.28% |
| 2019 Q2 | -727.05 Thousand AUD | 0.0% |
| 2019 Q4 | -1.16 Million AUD | 0.0% |
| 2019 FY | -1.92 Million AUD | 60.08% |
| 2018 FY | -4.82 Million AUD | 46.19% |
| 2018 Q4 | -1.81 Million AUD | 0.0% |
| 2018 Q2 | -2.51 Million AUD | 0.0% |
| 2017 FY | -8.96 Million AUD | -22.67% |
| 2017 Q2 | -3.49 Million AUD | 0.0% |
| 2017 Q4 | -3.64 Million AUD | 0.0% |
| 2016 FY | -7.31 Million AUD | -35.44% |
| 2016 Q4 | -2.84 Million AUD | 0.0% |
| 2016 Q2 | -2.17 Million AUD | 0.0% |
| 2015 Q3 | -1.34 Million AUD | 33.52% |
| 2015 Q2 | -2.03 Million AUD | -98.59% |
| 2015 Q1 | -1.02 Million AUD | 0.0% |
| 2015 FY | -5.39 Million AUD | -32.02% |
| 2015 Q4 | -3.36 Million AUD | -149.58% |
| 2014 Q3 | -1.02 Million AUD | 0.0% |
| 2014 Q1 | - AUD | 0.0% |
| 2014 Q4 | -1.02 Million AUD | 0.0% |
| 2014 FY | -4.08 Million AUD | -34.93% |
| 2014 Q2 | - AUD | 0.0% |
| 2013 FY | -3.03 Million AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | 15.901% |
| Acrux Limited | -9.83 Million AUD | 55.003% |
| Actinogen Medical Limited | -12.83 Million AUD | 65.535% |
| AnteoTech Limited | -11.72 Million AUD | 62.266% |
| Argenica Therapeutics Limited | -5.67 Million AUD | 21.975% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 38.483% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -203.262% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 77.426% |
| Avecho Biotechnology Limited | -4.58 Million AUD | 3.578% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -44.491% |
| Biome Australia Limited | -1.91 Million AUD | -131.282% |
| Biotron Limited | -5.15 Million AUD | 14.098% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 69.898% |
| BTC Health Limited | 1.05 Million AUD | 519.315% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 64.053% |
| CSL Limited | 5.64 Billion AUD | 100.078% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 90.123% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 109.003% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 49.761% |
| Dimerix Limited | -25.05 Million AUD | 82.342% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 145.541% |
| Hexima Limited | -1 Million AUD | -338.659% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -53.977% |
| Immuron Limited | -5.8 Million AUD | 23.722% |
| Immutep Limited | -44.93 Million AUD | 90.153% |
| Imugene Limited | -140.93 Million AUD | 96.86% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -107.392% |
| Memphasys Limited | -2.7 Million AUD | -63.645% |
| Nanollose Limited | -1.24 Million AUD | -254.047% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 101.958% |
| Noxopharm Limited | -7.53 Million AUD | 41.274% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -115.164% |
| Nyrada Inc. | -4.56 Million AUD | 2.968% |
| Orthocell Limited | -11.68 Million AUD | 62.119% |
| PharmAust Limited | -6.65 Million AUD | 33.545% |
| Patrys Limited | -3.53 Million AUD | -25.029% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 93.204% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 38.81% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 38.426% |
| PYC Therapeutics Limited | -38.85 Million AUD | 88.612% |
| Race Oncology Limited | -13.38 Million AUD | 66.93% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 90.627% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 79.933% |
| Starpharma Holdings Limited | -15.15 Million AUD | 70.81% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Tissue Repair Ltd | -4.87 Million AUD | 9.249% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 25.483% |